PB

Peter Bisgaard

Managing Director Pivotal Life Sciences Managing General Partner Pivotal bioVenture Partners

San Francisco Bay Area

Investor
VC

Invests in

Stages:

Series B
Series A

Sectors:

BioTech
San Francisco Bay Area

Locations:

San Francisco Bay Area
  • Min Investment:

    $100,000.00
  • Max Investment:

    $5,000,000.00
  • Target Investment:

    $1,500,000.00

Skills

Venture Capital
Biotechnology
Mergers & Acquisitions
Strategy
Corporate Finance

Education

  • D-

    M.Sc.

    DTU - Technical University of Denmark

Lists including Peter

AH
AE
AF
AJ

Based in SF

3077 people

AT
AS
AT
AH

All Series A Investors

14748 people

Investments

Engrail Therapeutics

Series A

Total Funding: $220M

Oculis

Series B

Total Funding: $190M

Eargo

Series C

Total Funding: $220M

OncXerna Therapeutics

Series B

Total Funding: $80M

Ceterix Orthopaedics

Series B

Total Funding: $18M

Otonomy

Series B

Total Funding: $180M

Nevro

Series C

Total Funding: $130M

Alder Biopharmaceuticals

Series D

Total Funding: $78M

Altheos

Series A

Total Funding: $33M

Light Sciences Oncology

Series A

Total Funding: $32M

Work Experience

PL
Pivotal Life Sciences

2017

  • Managing Director

    2017

NF Life Sciences

2017

  • Managing Director

    2017

N
Novo

2001 - 2017

  • Senior Partner

    2001 - 2017

McKinsey & Co.

1998 - 2001

  • Consultant

    1998 - 2001

All information is sourced from public domain and might be inaccurate.

|

By continuing, you're agreeing to our Terms and Privacy Policy.

|

Learn more About The Network.